Trials to assess safety and tolerability beyond 12 weeks are ongoing.
Cost-effectiveness analyses speculating on reductions in death and morbidity may be based on short-term randomized controlled trials. These results can overestimate what is achievable in practice.
Producing more lipid target 'responders' with ezetimibe will be appealing, despite the unknown consequences and increased costs. Recent evidence from statin trials suggests that potential benefits could depend on overall coronary artery disease risk and be less reflective of cholesterol levels. The theory that larger cholesterol reductions result in greater reductions in death and hospitalization is being tested with statins.